Back to Research & Reports

Disease Partnership Upfront Payments Hold Steady at an Average of $39 Million

BioCentury’s BCIQ Deal Charts: Third Quarter 2014 Highlight provides an informative overview of the state of dealmaking in the life sciences industry.

Learn which disease categories exhibited double-digit activity and received triple-digit upfront payments for pharmaceutical product, platform, therapeutic device and diagnostic partnerships. Developed in conjunction with BioCentury Publications, this report features a series of charts that sheds light on life sciences dealmaking for Q3 2014. A quick breakdown is included in each section, which ranges from top M&A buyers to top spenders in partnerships, providing you with a finger on the pulse of dealmaking in the industry.

What’s covered:

  • Industry partnerships in 2014 compared to the last three years, with additional insight into upfront payments involved in those deals
  • 2014 partnerships broken down by disease category with additional insight into upfront payments involved in those deals
  • Top spending companies by aggregate value of both upfront payments for partnerships and M&A activity

View Premium Content

Sign up once and access our entire library of premium content—white papers, webinars and reports—at any time.

All fields required*

 

I agree

This site uses cookies to offer you a better experience. For more information, view our privacy policy.